Topics

Newron Pharmaceutical S.p.A. Company Profile

20:05 EDT 20th July 2019 | BioPortfolio

Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The company is headquartered in Bresso near Milan, Italy. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the US, Australia, Canada, Brazil, and Colombia and is commercialized by Newron’s partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com


News Articles [394 Associated News Articles listed on BioPortfolio]

Newron Pharmaceuticals (NWRN) - Moving towards R&D inflection points

Edison Investment Research - Pharmaceuticals & healthcare - Newron Pharmaceuticals: Newron’s FY18 highlights the steady progression of its CNS R&D pipeline. STARS the pivotal Phase II/III (Sariz...

Newron Pharmaceuticals - Evenamide down but not out

Newron's plans for its novel mechanism of action drug, Evenamide, due to enter late-stage development for schizophrenia, have been delayed. Specifically, the FDA has requested that Newron carry out...

Newron completes patient enrollment in STARS Study

Newron expects to report top line results from the STARS study in Q4 2019. Rett syndrome, a severe neuro-developmental orphan disease with no approved treatment options, overwhelmingly affects The po...

Newron's commercialization partner Zambon and Valeo Pharma announce the launch of Onstryv (safinamide) for Parkinson's disease in Canada

Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5.XE), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and periphe...

Newron Pharmaceuticals: Commercialization Partner Zambon Together with Valeo Pharma Announce the Approval of Onstryv (safinamide) for Parkinson's Disease in Canada

Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous sys...

Newron Pharmaceuticals (NWRN) - Evenamide down but not out

Edison Investment Research - Pharmaceuticals & healthcare - Newron Pharmaceuticals: Newron's plans for its novel mechanism of action drug, Evenamide, due to enter late-stage development for schiz...

Newron Pharmaceuticals: Schweizer Probleme - Zweitlisting in Düsseldorf

Seit heute notieren die Aktien von Newron Pharmaceuticals an der Börse Düsseldorf. Die Papiere können auch via Xetra gehandelt werden. Die eigentliche Heimat der Newron-Aktien ist die Schweizer Bö...

Newron-Partner Zambon erhält mit Valeo Zulassung für Parkinson-Mittel in Kanada - Newron-Aktie im Aufwind

Dort werde es unter dem Namen Onstryv vermarktet werden.Wie es in der Mitteilung vom Mittwoch weiter hiess, hatten Newron-Partner Zambon und Valeo Pharma ihre Zusammenarbeit bereits zuvor bekannt g...

PubMed Articles [416 Associated PubMed Articles listed on BioPortfolio]

IPADAM "Pharmaceutical interventions on the issue of pharmaceutical records and self-medication" quanti survey in 482 French pharmacies.

This study aims to: (i) quantify the number of pharmaceutical interventions (PIs) linked to spontaneous requests for the two oral target molecules, ibuprofen and pseudoephedrine (ii) analyse the cause...

Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.

Clinical practice guidelines (CPGs) are important in advancing the quality of medical care. Financial relationships between physicians and pharmaceutical companies may influence clinical practice. In ...

H NMR analytical characterization of mineral oil hydrocarbons (PARAFFINS) for pharmaceutical use.

Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan.

Financial relationships between pharmaceutical companies and physicians can bias the conduct, findings, and reporting of clinical trials. In Japan, the valsartan scandal was a significant event: all 5...

Requirements for accurate H NMR quantification of mineral oil hydrocarbons (paraffins) for pharmaceutical or cosmetic use.

Clinical Trials [375 Associated Clinical Trials listed on BioPortfolio]

Clinical Impact of Pharmaceutical Consultations in Patients Treated for Chronic Obstructive Pulmonary Disease at Home

The implementation of pharmaceutical consultations in the city or at the hospital could modify the occurrence of exacerbations related to chronic obstructive pulmonary disease after return...

Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients.

Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for diabetes type 2 patients. Patients will be randomly allocated to th...

Improving Compliance Among Elderly Polypharmacy Users Through Community Pharmacy Based Pharmaceutical Care Program

The aim of the project is to evaluate effectiveness of a multidimensional pharmaceutical care plan in improving compliance among elderly polypharmacy users at community pharmacy settings. ...

Impact of Collaborative Pharmaceutical Care on Hospital Admission Drug Prescriptions for Patients 65 Years of Age and Older

The primary objective of this study is to evaluate the impact of the implementation of collaborative pharmaceutical care on drug support at admission for patients 65 years of age and older...

Companies [1070 Associated Companies listed on BioPortfolio]

Newron Pharmaceutical S.p.A.

Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The company is headquartered i...

Newron Pharmaceuticals S.p.A.

Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. The Compan...

Newron Pharmaceuticals SpA

Newron Pharmaceuticals SpA is a clinical stage biopharmaceutical company focused on the discovery and development of small molecule drugs for the treatment of central nervous system (CNS) diseases. Ou...

Pharmaceutical Online

Pharmaceutical Online, the pharmaceutical manufacturing industry’s leading Web site. Our online community serves the product-sourcing and information-seeking needs of pharmaceutical professionals wo...

Cypress Pharmaceutical, Inc.

Cypress Pharmaceutical, Inc., founded in 1993, is a specialty pharmaceutical company that develops, markets and distributes generic prescription pharmaceutical products to leading...

More Information about "Newron Pharmaceutical S.p.A." on BioPortfolio

We have published hundreds of Newron Pharmaceutical S.p.A. news stories on BioPortfolio along with dozens of Newron Pharmaceutical S.p.A. Clinical Trials and PubMed Articles about Newron Pharmaceutical S.p.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Newron Pharmaceutical S.p.A. Companies in our database. You can also find out about relevant Newron Pharmaceutical S.p.A. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record